This Medical Devices Stock Has Several Catalysts, Says Bullish Analyst
This Medical Devices Stock Has Several Catalysts, Says Bullish Analyst
Teleflex Inc (NYSE:TFX) benefited in the first quarter from the surge in the interventional segment and other tailwinds.
泰利福公司（NYSE: TFX）在第一季度受益於介入式業務部門的激增和其他助推因素。
UroLift sales in the physician's office could bottom out at $49 million in 2024 and the franchise will be "less of a revenue headwind" from 2025, according to Piper Sandler.
根據派傑投資公司的說法，醫生診所的UroLift銷售額可能在2024年達到4,900萬美元，並且從2025年開始，該產品系列將成爲“收入的幫助”，而非“拖累”產品系列。
The Teleflex Analyst: Matt O'Brien upgraded the rating for Teleflex from Neutral to Overweight, while raising the price target from $205 to $245.
泰利福分析師馬特•奧布萊恩將泰利福的評級從中立提升至超重，同時將價格目標由205美元上調至245美元。
The Teleflex Thesis: UroLift sales, which has prevented the stock from performing in recent quarters, should trough in the second or third quarter this year, O'Brien said in the upgrade note.
奧布賴恩在升級公告中表示，UroLift的銷售額曾使該公司股票在近幾個季度的表現不佳，但這種局面應該在今年第二或第三季度觸底。
Check out other analyst stock ratings.
查看其他分析師的股票評級。
The company's sole competitor in the IABP market, Getinge is "facing significant regulatory issues with its production and sale of product, which makes about $170M worth of annual revenue potentially available to Teleflex," the analyst wrote.
該公司在IABP市場上唯一的競爭對手，Geitnge公司正面臨“生產和銷售產品方面存在重大監管問題，這將使每年約1.7億美元的收入潛在地可以轉化爲泰利福的收入，”，分析師寫道。
He added that the impact of this could be felt in 2025, adding about 100-200 basis points to revenue and earnings growth.
他補充說，這可能會在2025年產生影響，爲營業收入和創業板增長帶來約100-200個點子的貢獻。
"We continue to get good feedback on the Barrigel product that TFX acquired last year and believe this product could grow north of 20% for several years," O'Brien further stated.
奧布賴恩進一步指出：“我們繼續收到關於TFX去年收購的Barrigel產品的好反饋，並認爲該產品未來幾年的增長可能超過20%。”
TFX Price Action: Shares of Teleflex had risen by 1.7% to $213.92 at the time of publication on Monday.
泰利福股票在週一出版時上漲了1.7%，報213.92美元。
Now Read:
現在就閱讀吧:
- Trump Granted Partial Immunity By Supreme Court, Ruling Says 'The President Is Not Above The Law': Dissenting Justice Criticizes Mockery Of Constitution
- 最高法院授予特朗普部分豁免權，裁決稱“總統不凌駕於法律之上”：反對意見的法官批評了違反憲法的行爲。